An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF
(Avastin) therapy in any Genentech-sponsored Phase I or Phase II cancer study and who did not
show evidence of disease progression at completion of the parent study will be eligible for
inclusion in this trial.